Relationship between the status of cell cycle- and apoptosis-regulatory genes and sensitivity to radio-chemotherapy for malignant astrocytic tumors.
细胞周期和凋亡调节基因的状态与恶性星形细胞肿瘤放化疗敏感性之间的关系。
基本信息
- 批准号:10557126
- 负责人:
- 金额:$ 8.77万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B).
- 财政年份:1998
- 资助国家:日本
- 起止时间:1998 至 2000
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Our study on p53 gene mutation in astrocytic tumors disclosed the importance to understand how low grade tumors recur and progress to malignant lesions since this dramatically shortens patient survival. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. Frequent co-alterations of TP53, p16/CDKN2A, p14 (ARF), PTEN tumor suppressor genes indicate the importance of developing therapeutic approaches applicable to tumors with a broad range of genetic alterations. In order to understand the influence of the functional status of p53 on the sensitivity to anticancer agents and radiotherapy, we analyzed responses of LN382 cells containing a temperature-sensitive mutant p53 at 34 degrees and 37 degrees to etoposide, paclitaxel, cisplatin, and ACNU.Restoration of p53 protein function in LN382 cells at 34 degrees reduced the cytotoxicity of etoposide and paclitaxel, whereas that of cisplatin, but not of ACNU.Transduction of wild-type p53 in LN382 cells also reduced the sensitivity of the cells to etoposide. Cell cycle analysis revealed that this decrease in sensitivity was associated with an impaired transition to the G2M phase subsequent to the addition of etoposide or paclitaxel. The cell cycle arrest induced by wild-type p53 function may abrogate the cytotoxic effects of etoposide and paclitaxel, which are dependent on G2M-associated apoptosis. On the other hand, p21 expression by restoration of p53 function can increase the radiosensitivity of glioblastoma cells by arresting the cells at G1 and G2M phases. To study the feasibility of gene therapy in malignant gliomas, we examined the antiproliferative effect of the adenovirally transduced wild-type p53 tumor suppressor gene by using 15 different high-grade glioma cell lines and found that CAR expression is a critical determinant of transduction efficiencies in adenovirus-based gene therapy for human malignant gliomas.
我们对星形细胞肿瘤p53基因突变的研究揭示了了解低级别肿瘤如何复发并进展为恶性病变的重要性,因为这大大缩短了患者的生存期。低级别星形细胞肿瘤中TP 53突变的细胞克隆性发展为恶性,是一个不利的预后因素。TP 53、p16/CDKN 2A、p14(ARF)、PTEN肿瘤抑制基因的频繁共改变表明开发适用于具有广泛遗传改变的肿瘤的治疗方法的重要性。为了了解p53的功能状态对抗癌剂和放射治疗敏感性的影响,我们分析了含有温度敏感性突变体p53的LN 382细胞在34度和37度对依托泊苷、紫杉醇、顺铂和ACNU的反应。在34度下,LN 382细胞中p53蛋白功能的恢复降低了依托泊苷和紫杉醇的细胞毒性,转染野生型p53基因的LN 382细胞对足叶乙甙的敏感性也降低。细胞周期分析显示,这种敏感性的降低与加入依托泊苷或紫杉醇后向G2 M期的过渡受损有关。由野生型p53功能诱导的细胞周期阻滞可能消除依托泊苷和紫杉醇的细胞毒性作用,这依赖于G2 M相关的凋亡。另一方面,通过恢复p53功能的p21表达可以通过使胶质母细胞瘤细胞停滞在G1和G2 M期来增加胶质母细胞瘤细胞的放射敏感性。为了研究基因治疗在恶性胶质瘤中的可行性,我们通过使用15种不同的高级别胶质瘤细胞系来检查腺病毒转导的野生型p53肿瘤抑制基因的抗增殖作用,并且发现CAR表达是基于腺病毒的基因治疗人类恶性胶质瘤的转导效率的关键决定因素。
项目成果
期刊论文数量(40)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Ishii N: "Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines."Brain Pathol. 9. 469-479 (1999)
Ishii N:“人类神经胶质瘤细胞系中 TP53、p16/CDKN2A、p14ARF、PTEN 肿瘤抑制基因的频繁共同改变。”Brain Pathol。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Ishii N, et al.: "Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor."Oncogene. 18. 5870-5878 (1999)
Ishii N 等人:“低度星形细胞肿瘤中具有 TP53 突变的细胞会克隆性地演变成恶性肿瘤,并且是不利的预后因素。”Oncogene。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Ikeda J: "Roles ofp53 in chemotherapy of glioblastoma."Hokkaido J Med Sci. 75. 299-314 (2000)
Ikeda J:“p53 在胶质母细胞瘤化疗中的作用。”Hokkaido J Med Sci。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Asaoka K, et al.: "Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor."J Neurosurg. 92. 1002-1008 (2000)
Asaoka K 等人:“恶性神经胶质瘤细胞中有效腺病毒基因传递对柯萨奇病毒和腺病毒受体表达水平的依赖性。”J Neurosurg。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
多田光宏: "p53の変異とその機能的影響" 佐谷秀行監修 : p53-癌抑制の分子メカニズムと臨床応用, 秀潤社, 142 (1998)
Mitsuhiro Tada:“P53突变及其功能效应”由Hideyuki Saya监督:p53癌症抑制的分子机制和临床应用,Shujunsha,142(1998)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SAWAMURA Yutaka其他文献
SAWAMURA Yutaka的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SAWAMURA Yutaka', 18)}}的其他基金
Investigation for oncogenes relating to chemotherapy resistance of human malignant gliomas
人恶性胶质瘤化疗耐药相关癌基因的研究
- 批准号:
14571295 - 财政年份:2002
- 资助金额:
$ 8.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of genetic diagnostics of brain tumors : Rapid diagnosis of mutation of p53 tumor suppressor gene.
脑肿瘤基因诊断的建立:p53抑癌基因突变的快速诊断。
- 批准号:
08457355 - 财政年份:1996
- 资助金额:
$ 8.77万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Molecular genetic study on the relation of parental alleles to the loss of tumor suppressor genes in gliomas.
亲本等位基因与胶质瘤抑癌基因缺失关系的分子遗传学研究。
- 批准号:
04670846 - 财政年份:1992
- 资助金额:
$ 8.77万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似海外基金
INVOLVEMENT OF CELL CYCLE REGULATORS IN NEURONAL DEATH
细胞周期调节因子参与神经元死亡
- 批准号:
2714571 - 财政年份:1995
- 资助金额:
$ 8.77万 - 项目类别:
INVOLVEMENT OF CELL CYCLE REGULATORS IN NEURONAL DEATH
细胞周期调节因子参与神经元死亡
- 批准号:
2431283 - 财政年份:1995
- 资助金额:
$ 8.77万 - 项目类别:
INVOLVEMENT OF CELL CYCLE REGULATORS IN NEURONAL DEATH
细胞周期调节因子参与神经元死亡
- 批准号:
2273620 - 财政年份:1995
- 资助金额:
$ 8.77万 - 项目类别:
Cell Cycle Regulators in Pancreatic Development and Disease
胰腺发育和疾病中的细胞周期调节因子
- 批准号:
9356143 - 财政年份:
- 资助金额:
$ 8.77万 - 项目类别:














{{item.name}}会员




